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Objectives: We evaluated treatment outcomes and predictors for poor treatment outcomes 67 
for tuberculosis (TB) among native- and foreign-born patients with drug-susceptible TB 68 
(DSTB) in the Netherlands. 69 
Methods: This retrospective cohort study included adult patients with DSTB treated from 70 
2005 to 2015 from a nationwide exhaustive registry. Predictors for unsuccessful treatment 71 
outcomes (default and failure) and TB-associated mortality were analysed using multivariate 72 
logistic regression. 73 
Results: Among 5,674 identified cases, the cumulative incidence of unsuccessful treatment 74 
and mortality were 2.6% (n/N = 146/5,674) and 2.0% (112/5,674), respectively. Although 75 
most patients were foreign-born (71%; 4,042/5,674), no significant differences in these 76 
outcomes were observed between native- and foreign-born patients (p > 0.05). Significant 77 
predictors for unsuccessful treatment were age of 18–24 years [odds ratio (OR), 2.04; 95% 78 
confidence interval (CI): 1.34–3.10], homelessness (OR, 2.56; 95% CI: 1.16–5.63), prisoner 79 
status (OR, 5.39; 95% CI: 2.90–10.05) and diabetes (OR, 2.02; 95% CI: 1.03-3.97). 80 
Furthermore, predictors for mortality were age of 74–84 (OR, 5.58; 95% CI: 3.10–10.03) or 81 
≥85 years (OR, 9.35, 95% CI: 4.31–20.30), combined pulmonary and extra-pulmonary TB 82 
(OR, 4.97; 95% CI: 1.42–17.41), central nervous system (OR, 120, 95% CI: 34.43–418.54) 83 
or miliary TB (OR, 10.73, 95% CI: 2.50–46.02), drug addiction (OR, 3.56; 95% CI: 1.34–9.47) 84 
and renal insufficiency/dialysis (OR, 3.23; 95% CI: 1.17–8.96). 85 
Conclusions: Native- and foreign-born patients exhibited similar TB treatment outcomes. To 86 
further reduce disease transmission and inhibit drug resistance, special attention should be 87 
given to high-risk patients. 88 
 89 
















Although tuberculosis (TB) is a global health problem [1], the associated burden in Europe 92 
has been mainly attributed to the travel and migration of people from high- to low-TB burden 93 
countries [2–4]. Several groups, including immigrants, asylum seekers, prisoners and 94 
homeless individuals, have been identified as high-risk groups [4,5]. Hence, adequate 95 
treatment management is required, especially for high-risk groups. 96 
The Netherlands has a low TB incidence, with an estimated incidence of 5.9/100,000 97 
population in 2016 [5]. According to the Netherlands Tuberculosis Registry (NTR), drug-98 
susceptible TB (DSTB) is the most common form of TB in the Netherlands. From 2005 to 99 
2015, 72% of cases (n/N= 7,416/10,303) were identified as using standard treatment for 100 
DSTB. A previous study from the Netherlands (1993–1997) identified a higher probability of 101 
treatment default among asylum seekers, immigrants and illegal immigrants [6]. However, 102 
updated data are needed to determine whether being in a risk group or other factors 103 
contribute to poor outcomes of TB treatment and to evaluate the success of current 104 
treatment programmes in the Netherlands. We therefore aimed to evaluate treatment 105 
outcomes and predictors for poor treatment outcomes for tuberculosis (TB) among native- 106 



























Study design and setting 120 
This retrospective cohort study included patients treated for DSTB between 1 January 2005 121 
and 31 December 2015. Anonymised data were obtained from the NTR database on 23 122 
January 2017 following approval from the NTR committee. The NTR is an exhaustive 123 
national database managed by the Dutch National Institute for Public Health and the 124 
Environment (RIVM). Real-time surveillance data are routinely collected by RIVM in close 125 
collaboration with the TB control department of the Municipal Public Health Services (MPHS) 126 
and Royal Netherlands Tuberculosis Association/ KNCV TB. MPHS are legally required to 127 
record and register all patients with TB in the Netherlands, including those treated in 128 
hospitals. NTR data collection occurs throughout the TB diagnostic and treatment period, 129 
and the information is entered by the physician or nurse into an electronic report via the 130 
Online Registration System for Infectious Diseases in Infectious Diseases Surveillance 131 
Information System (OSIRIS) after the diagnosis is made. KNCV TB and MPHS check the 132 
registrations for completeness and consistency through an interactive process. MPHS 133 
receives reminders when records remain incomplete. The online system enables MPHS to 134 
correct and add information to patient records.  135 
 136 
Study subjects 137 
We included patients with TB aged ≥18 years who were registered in the NTR database and 138 
classified as being infected with Mycobacterium tuberculosis strain that was considered fully 139 
sensitive to first-line anti-TB drugs and treated during the study period. From this cohort of 140 
eligible patients, those with an unknown treatment outcome, i.e. no treatment initiated, 141 
treatment ongoing and treatment continued elsewhere with unknown results during a 1-year 142 


















Potential predictors and definitions 147 
Potential predictors for a poor outcome of TB treatment were identified at baseline (before or 148 
during diagnosis) to predict the incidence of the study outcome. We selected a set of 149 
potential predictors based on previously published articles (see Supplementary 1), input 150 
from TB practitioners and information from the NTR database. These potential predictors 151 
were classified into five categories: (1) socio-demographic characteristics (age, sex, birth 152 
country, domicile area, insurance coverage for TB), (2) current TB diagnosis (pulmonary TB 153 
type, TB location, place of diagnosis, treatment delay), (3) history of TB disease and 154 
treatment [previously diagnosed TB, treated latent TB infection (LTBI), Bacillus Calmette–155 
Guérin (BCG) vaccination status] (4) risk groups (those in contact with patients with TB, 156 
immigrants, asylum seekers, illegal immigrants, homeless individuals, healthcare workers, 157 
travellers from/in endemic area, prisoners, alcohol and drug addicts) and (5) high-risk 158 
comorbidities [diabetes, human immunodeficiency virus (HIV), malignancy, renal 159 
insufficiency/dialysis, organ transplantation]. 160 
 161 
Primary outcomes 162 
We retrospectively followed patients from the beginning to the end of DSTB treatment for one 163 
episode of TB during a 1-year period. According to the WHO criteria [7], we categorised the 164 
study outcomes into unsuccessful treatment and TB-associated mortality. Unsuccessful 165 
treatment was defined as a combination of defaulted and failed treatment. Treatment default 166 
cases met one of the following four conditions: interruption of TB treatment for ≥2 167 
consecutive months, incomplete treatment for 6 months within a 9-month treatment period, 168 
incomplete treatment for 9 months within a 12-month treatment period and completion of 169 
<80% of the treatment. Failed treatment was defined as a positive sputum smear or culture 170 
at 5 months or more after treatment initiation. For extra-pulmonary TB, treatment failure was 171 
defined by a physician according to a national guideline [8]. All treatment outcomes were 172 















variables followed those in the manual OSIRIS guideline published by RIVM [9] 174 
(Supplementary Table S1). 175 
 176 
Statistical analysis 177 
Distributions of subjects' characteristics and the cumulative incidences were examined using 178 
descriptive statistics. The cumulative incidence of the study outcomes were calculated by 179 
dividing incidence of the outcome with the number of DSTB cases during the observation 180 
period. We eliminated potential predictors if >10% of the data were missing. We used the chi-181 
square test or Fisher’s exact test (when expected cell size was <5) for univariate analyses of 182 
categorical covariates. Variables with a p-value of <0.25 in the univariate analysis were 183 
considered for inclusion in the multivariate analysis. If the number of variables exceeded the 184 
assumption of 10 events per variable examined, we considered a stricter univariate p-value 185 
(<0.15) for inclusion in the multivariate analysis [10]. To increase the statistical power and 186 
validity, we minimised the degree of freedom in the predictor model by combining predictors 187 
that measured a similar concept and had similar estimated risks in the univariate analysis 188 
[10]. Variables for which there were no incidences of the study outcome in the indicator 189 
group were not included in the multivariate analysis. A backward step elimination based on a 190 
p-value of >0.05 was used for the multivariate analysis. We used complete case analysis that 191 
excluded patients with missing values [10]. Odds ratios (ORs) with 95% confidence intervals 192 
(CIs) were calculated to quantify the level of association between variables and outcomes. 193 
The calibration of the multivariate analysis model was assessed using the Hosmer–194 
Lemeshow test, while discrimination was estimated using a receiver operating characteristic 195 
curve with a 95% CI. We used Statistical Package for the Social Science, version 23 (SPSS; 196 
IBM Corp., NY, USA) for Windows™ in all statistical analyses; a final p-value of <0.05 was 197 
considered significant in the multivariate analysis. We followed the STROBE guidelines for 198 
reporting this study [11]. 199 
















Baseline characteristics of study subjects 202 
Of the 10,303 adult cases with TB registered during the study period, we identified 5,674 203 
cases with DSTB who fulfilled the study criteria (Figure 1). Most patients with DSTB were 204 
foreign-born (71%, n/N = 4,042/5,674; Table 1). As described in Figure 1, 192 patients with 205 
DSTB were lost to observation and had missing information about treatment outcomes. 206 
Missing information about TB treatment outcomes was significantly more frequent (p < 0.05) 207 
among males, foreign-born patients, prisoners, those with pulmonary TB, those with TB 208 
diagnosis from outside the Netherlands, immigrants, illegal immigrants and those with a 209 
history of travel from/to an endemic area >3 months earlier (Supplementary Table S2). 210 
 211 
Incidence of DSTB 212 
We observed a significant declining trend in the number of DSTB cases within the study 213 
period (p <0.05), with cumulative incidences of unsuccessful TB treatment and TB-214 
associated mortality as 2.6% (146/5,674) and 2.0% (112/5,674), respectively. The highest 215 
annual cumulative incidence for both these outcomes was identified in 2011 (Fig. 2). 216 
 217 
Predictors for outcomes 218 
We combined asylum seekers and immigrants as one covariate in the analysis because 219 
similar residential status outside the Netherlands was thought to yield relatively similar 220 
statistical associations in the univariate analysis. In the univariate analysis, immigrants and 221 
asylum seekers had ORs (95% CI) of 0.90 (0.48–1.67) and 1.57 (0.97–2.54) for unsuccessful 222 
treatment outcome, while for mortality outcome had ORs (95% CI) of 0.19 (0.05–0.80) and 223 
0.09 (0.12–0.62), respectively.  224 
In the univariate analysis, sex, age, homelessness and prisoner status were 225 
significantly associated (p < 0.05) with unsuccessful treatment. Furthermore, multivariate 226 
analyses revealed a final prediction model comprising age of 18–24 years (OR, 2.04; 95% 227 















95% CI: 2.90–10.05) and diabetes (OR, 2.02; 95% CI: 1.03–3.97) as significant predictors for 229 
unsuccessful treatment (Table 2). 230 
Regarding mortality, age; pulmonary diagnostic type; initial TB location, such as lung, 231 
CNS and miliary TB; previous TB diagnosis; non-immigrant status; non-asylum seeker; 232 
native-born status and comorbidities, such as diabetes, malignancy, renal 233 
insufficiency/dialysis and organ transplantation, were significantly associated with death in 234 
the univariate analysis (p < 0.05). Finally, we identified age of 75–84 (OR, 5.58; 95% CI: 235 
3.10–10.03) or ≥85 years (OR, 9.35; 95% CI: 4.31–20.30), combined pulmonary and extra-236 
pulmonary TB (OR, 4.97; 95% CI: 1.42–17.41), central nervous system (OR, 120; 95% CI: 237 
34.43–418.54) or miliary TB (OR, 10.73; 95% CI: 2.50–46.02), drug addiction (OR, 3.56; 238 
95% CI: 1.34–9.47), renal insufficiency/dialysis (OR, 3.23; 95% CI: 1.17–8.96) and immigrant 239 
or asylum seeker status (OR, 0.11; 95% CI :0.01–0.84) as significant predictors for mortality 240 
















Although most cases in our study involved foreign-born patients, no significant differences in 243 
treatment outcomes were observed between native- and foreign-born patients. Immigrants 244 
and asylum seekers had a lower risk of death than other patients and no significant 245 
difference in the risk for unsuccessful TB treatment. Overall, approximately 5 in 100 treated 246 
DSTB cases had a poor TB treatment outcome, of which 2.6% (146/5,674) were attributed to 247 
unsuccessful treatment and 2.0% (112/5,674) to TB-associated mortality. Predictors for 248 
unsuccessful treatment included age of 18–24 years, homelessness, prisoner status and 249 
diabetes. Furthermore, age of ≥75 years, drug addiction, combined pulmonary and extra-250 
pulmonary TB and several comorbidities [renal insufficiency, central nervous system (CNS) 251 
and miliary TB] were predictors for TB-associated mortality. Moreover, male sex, foreign-252 
born patients, immigrants, illegal immigrants, travellers from/in endemic areas for >3 months, 253 
those diagnosed with TB from outside of the Netherlands, those with pulmonary TB and 254 
prisoners were more likely to be lost to treatment follow-up which indicates potential high risk 255 
of poor outcomes. 256 
Diabetes was identified as a risk factor for unsuccessful TB treatment in this study. 257 
Previous studies have demonstrated that the correlation of diabetes with TB treatment failure 258 
[12] could be attributed to altered drug absorption [13] and immune system as well as drug 259 
interaction [14]. We further identified renal insufficiency/dialysis as a risk factor for TB-260 
associated mortality. In patients undergoing dialysis, altered immune response associated 261 
with uraemia and dialysis exacerbation have been identified as predisposing factors for 262 
active TB development [15]. Patients with end-stage renal disease are more susceptible to 263 
TB [16]. Furthermore, drug-induced hepatitis has been identified more frequently in patients 264 
with TB and chronic renal failure than in those with TB but without chronic renal failure that 265 
increase the risk of TB-associated mortality [17]. 266 
Our finding of age being a relevant predictor was supported by a retrospective 267 















(age <25 years) more likely defaulted treatment [18]. Moreover, a multi-centre prospective 269 
cohort study in Spain reported that elderly people were more likely to die from TB [19]. 270 
A previous Dutch study (1993–1997) showed an association between the risk of 271 
treatment default and being in the high-risk group (asylum seekers, immigrants, illegal 272 
immigrants, homeless individuals, prisoners and eastern European nationals) [6]. However, 273 
the present study did not show that immigrants and asylum seekers as a high-risk group in 274 
terms of outcomes (unsuccessful treatment and TB-associated mortality). It seems that 275 
asylum seekers and immigrants received a successful treatment during the study period.  276 
According to the national guideline, immigrants and asylum seekers comprise a high-277 
risk priority group for TB screening and monitoring [20]. People from TB-endemic countries 278 
who plan to reside in the Netherlands for >3 months are required to undergo regular chest X-279 
ray for 2 years. TB diagnosis leads to the administration of regular treatment and monitoring, 280 
together with treatment support from a nurse at Municipal Public Health Services. To ensure 281 
TB treatment compliance, municipal health centres work closely with medical service 282 
providers to asylum seekers and prisoners as well as with social workers from institutions for 283 
homeless care. Total TB control expenditures are covered by health insurance and funding 284 
from municipal authorities and the government [21]. For uninsured patients, the treatment 285 
cost is covered by municipalities via the public health act or budgeted financial support for 286 
illegal immigrants [22]. Two modern TB hospitals have been established for the long-term 287 
admission and specialised treatment of clinically complex or socially problematic TB cases to 288 
support successful treatment [23]. TB management is standardised according to a national 289 
TB guideline [8] and framework of the National Tuberculosis Control and Plan [21]. 290 
We identified homeless individuals and prisoners as being at a risk of unsuccessful 291 
TB treatment and drug addicts as a dominant risk group for TB-associated mortality. These 292 
vulnerable and hard-to-reach patients have both individual problems and challenges related 293 
to healthcare facility access. Specifically, individuals in these groups lack awareness and 294 
knowledge of TB and experience stigma, unstable accommodation and challenges in terms 295 















homeless individuals, prisoners or HIV-positive [25], all of which further increase the risk of 297 
poor TB treatment outcome. Therefore, hard-to-reach patients should be admitted into a 298 
modern TB hospital to intensify treatment and monitoring and enable successful outcomes. 299 
Our results were inconsistent with those of several other local studies regarding the 300 
determinants for poor TB treatment outcomes in Pakistan [26], China [27], South Korea [28], 301 
and Germany [29]. For instance, a study in Hamburg identified alcohol dependence as a 302 
determinant for disease persistence and treatment interruption. These inter-study differences 303 
can be explained by differences in risk factors across settings due to differences in 304 
healthcare systems, government support and patients' social, clinical and behavioural 305 
characteristics. Previous analyses also included subjects with drug-resistant TB, a specific 306 
high-risk group that requires longer and other treatment, and more study on their prognosis is 307 
needed. 308 
Several potential limitations need to be acknowledged. First, because we used data 309 
from an administrative database, our dataset relied on reports from clinicians without any 310 
direct observations by current investigators, which may have led to inaccuracies. Second, 311 
several prominent predictors which may have further increased the discriminative value of 312 
multivariate models, such as HIV, treatment delay duration, BCG vaccination history, 313 
insurance coverage, education level, income and patient beliefs, could not be analysed due 314 
to unavailability of data for a large number of patients. Third, a low mortality rate in this study 315 
led to low precision of the associations between mortality outcome and some predictors, 316 
such as age and initial TB location (CNS and miliary TB). However, we believe that the 317 
systematic approach for data collection supported by information technology, national 318 
guideline, control system for data collection and an integrated referral system for patients 319 
with TB in the Netherlands led to a minimal bias in this study. Importantly, expanding the 320 
national database coverage to include patients throughout the Netherlands will improve the 321 
applicability of our results to the Dutch DSTB population. 322 
In conclusion, although most DSTB cases included foreign-born patients, these 323 















observed a relatively low incidence of unsuccessful TB treatment and TB-associated 325 
mortality among DSTB cases in the Netherlands. However, to reduce further disease 326 
transmission and inhibit drug resistance, the potential for unsuccessful treatment should be 327 
considered among patients with DSTB aged 18–24 years and those who are homeless, 328 
prisoners or diabetic. Furthermore, patients aged ≥75 years, drug addicts, those diagnosed 329 
with CNS TB, miliary TB, renal insufficiency comorbidity, combined pulmonary and extra-330 
pulmonary TB should be carefully monitored to prevent premature mortality. Further study is 331 
needed to investigate the quality of TB management, barriers and effective interventions for 332 
improved treatment in high-risk groups. 333 
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FIGURES AND TABLES 465 
466 
Figure 1. Flow diagram of the included subjects. M. tb, Mycobacterium tuberculosis; H, 467 
isoniazid; R, rifampicin; E, ethambutol; Z, pyrazinamide; MDR, multi-drug-resistant; XDR, 468 




Figure 2. Annual cumulative incidence for TB treatment outcomes during 2005–2015. DSTB, 473 





























Table 1. Characteristics of subjects (N = 5,674) 489 
No Characteristics Frequency (%) 
1 Socio-demographic  
 Male 3,426 (60.4) 
 Age (years):  
 18–24 867 (15.3) 
 25–74 4,246 (74.8) 
 75–84 422 (7.2) 
 ≥85 139 (2.4) 
 Country of birth*:  
 The Netherlands 1,617 (28.5) 
 Somalia 741 (13.1) 
 Maroco 539 (9.5) 
 Indonesia 275 (4.8) 
 Suriname 274 (4.8) 
 Turkey 187 (3.3) 
 Others 2,041 (36) 
 Urban domicile† 1,997 (35.2) 
 Insurance coverage for TB*§ 57 (10.3) 
2 Current TB diagnosis  
 Pulmonary diagnosis  
 ETB 1,890 (33.3) 
 PTB 3,012 (53.1) 
 ETB + PTB 772 (13.6) 
 Initial TB location  
 Lungs 3,505 (61.8) 
 Central nervous system 70 (1.2) 
 Miliary 125 (2.2) 
 Others 1,974 (34.8) 
 TB diagnosis outside of the Netherlands 50 (0.9) 
 Treatment delay >4 weeks* 1,053 (18.5) 
3 History of TB disease & treatment  
 Previously diagnosed TB* 358 (6.3) 
 Previously treated LTBI* 184 (3.2) 
 BCG vaccination* 1,555 (27.4) 
4 TB risk group  
 TB contact 375 (6.6) 
 Immigrant 471 (8.3) 















 Illegal immigrant 201 (3.5) 
 Homeless individuals 132 (2.3) 
 Health care workers 46 (0.8) 
 Travelers from/in endemic area >3 month 130 (2.3) 
 Prisoners 143 (2.5) 
 Alcohol addicts 111 (2.0) 
 Drug addicts 152 (2.7) 
5 Comorbidities  
 Diabetes 268 (4.7) 
 HIV positive 229 (4.0) 
 Malignancy 135 (2.4) 
 Renal insufficiency/ dialysis 91 (1.6) 
 Organ transplantation 22 (0.4) 
6 Outcomes 
 
 Cure or completed treatment 5,190 (91.5) 
 Defaulted treatment 144 (2.5) 
 Failed treatment 2 (0.0) 
 Death due to TB 112 (2.0) 
 Death due to non-TB 226 (4.0) 
 490 
Notes: *missing data : Country of birth 15 (0.3%), Previously diagnosed TB 437 (7.7%), Previously 491 
treated LTBI 466 (8.2%), BCG vaccination 2,812 (49.6%), HIV positive 3,329 (58.7%), treatment delay 492 
4,056 (71.5), insurance coverage for TB 5,062 (89.2%); §the information was documented from 2014; 493 
†Urban domicile : Amsterdam, Rotterdam, the Hague and Utrecht; TB, tuberculosis; ETB, extra-494 
pulmonary tuberculosis; PTB, pulmonary tuberculosis; LTBI, latent tuberculosis infection; BCG, 495 















Table 2. Predictors for unsuccessful tuberculosis treatment outcome (N = 5,674) 
No Predictors Unsuccessful treatment  Univariate analysis Multivariate analysis* 
No (n = 5,528; %) Yes (n= 146; %) OR (95%CI) p-value aOR (95%CI) p-value 
1 Socio-demographic 
characteristics 
      
 Male 3325 (60.1) 101 (69.2) 1.35 (1.04-1.76) 0.025 1.35 (0.91-2.01) 0.13 
 Age (years)    0.000  0.004 
 18–24 834 (15.1) 33 (22.6) 1.66 (1.11-2.48)  2.04 (1.34-3.10)  
 25–74 4147 (75) 99 (67.8) Ref.  Ref.  
 75–84 415 (7.5) 7 (4.8) 0.71 (0.33-1.53)  0.83 (0.36-1.93)  
 ≥85 132 (2.4) 7 (4.8) 2.22 (1.01-4.87)  2.24 (0.89-5.67)  
 Born in the Netherlands** 1579 (28.6) 38 (26.2) 0.89 (0.61-1.29) 0.52 Not included - 
 Urban domicile 1946 (35.2) 51 (34.9) 0.99 (0.70-1.40) 0.95 Not included - 
2 Current TB diagnosis 
      
 Pulmonary diagnosis    0.76 Not included - 
 ETB 1839 (33.3) 51 (34.9) Ref.    
 PTB 2934 (53.1) 78 (53.4) 0.96 (0.67-1.37)    
 ETB + PTB 755 (13.7) 17 (11.6) 0.81 (0.47-1.42)    
 Initial TB location    0.11  0.52 
 Lungs 3416 (61.8) 89  (61) 0.89 (0.64-1.25)  0.75 (0.52-1.10)  
 Central nervous system 70 (1.3) 0 (0) n/a  n/a  
 Miliary 124 (2.2) 1 (0.7) 0.28 (0.04-2.01)  n/a  
 Others 1918 (34.7) 56 (38.4) Ref.  Ref.  
 TB diagnosis outside of the 
Netherlands 
48 (0.9) 2 (1.4) 1.59 (0.38-6.58) 0.37 Not included - 
3 History of TB disease & 
treatment 
      
 Previously diagnosed TB** 345 (6.8) 13 (9.8) 1.50 (0.84-2.68) 0.17 1.46 (0.75-2.81) 0.26 
 Previously treated LTBI** 177 (3.5) 7 (5.3) 1.56 (0.72-3.39) 0.23 1.82 (0.83-4.00) 0.14 
4 TB risk group 
      
 TB contacts 366 (6.6) 9 (6.2) 0.93 (0.47-1.83) 0.83 Not included - 
 Immigrants & asylum seekers 966 (17.5) 31 (21.2) 1.27 (0.85-1.90) 0.24 1.34 (0.84-2.14) 0.22 
 Illegal immigrants 198 (3.6) 3 (2.1) 0.57 (0.18-1.79) 0.32 Not included - 
 Homeless individuals 123 (2.2) 9 (6.2) 2.89 (1.44-5.80) 0.007 2.56 (1.16-5.63) 0.02 
 Health care workers 46 (0.8) 0 (0) 0.40 (0.02-6.56) 0.52 Not included  
 Travelers from/in endemic area 
>3 month 















 Prisoners 127 (2.3) 16 (11) 5.23 (3.03-9.06) 0.000 5.39 (2.90-10.05) 0.000 
 Alcohol addicts 107 (1.9) 4 (2.7) 1.43 (0.52-3.93) 0.54 Not included - 
 Drug addicts 146 (2.6) 6 (4.1) 1.58 (0.69-3.64) 0.28 Not included - 
5 Comorbidities 
      
 Diabetes 257 (4.6) 11 (7.5) 1.67 (0.89-3.13) 0.11 2.02 (1.03-3.97) 0.04 
 Malignancy 129 (2.3) 6 (4.1) 1.79 (0.78-4.14) 0.16 2.09 (0.81-5.35) 0.13 
 Renal insufficiency/dialysis 91 (1.6) 0(0) 0.20 (0.01-3.28) 0.26 Not included - 
 Organ transplantation 21 (0.4) 1 (0.7) 1.81 (0.24-13.54) 0.44 Not included - 
 
Notes: *Number of analysed cases, 5,674; Hosmer & Lemeshow test, 0.99; area under the curve, 0.64 (0.59–0.69); n/a, not applicable due to a small number 
of events; Ref., reference; OR, odds ratio; aOR, adjusted odds ratio; **missing values: country of birth, 15 (0.3%); previous TB diagnosis, 437 (7.7%); previous 
































Table 3. Predictors for mortality outcome due to tuberculosis (N = 5,674) 
No Predictors Mortality due to TB Univariate analysis Multivariate analysis* 
No (n=5,562; %) Yes (n=112; %) OR (95%CI) p-value aOR (95% CI) p-value 
1 Socio-demographic 
characteristics 
      
 Male 3354 (60.3) 72 (64.3) 1.19 (0.80-1.75) 0.39 Not included - 
 Age (years)    0.000  0.000 
 18–24 863 (15.5) 4 (3.6) 0.31 (0.11-0.86)  0.45 (0.13-1.52)  
 25–74 4184 (75.2) 62 (55.4) Ref  Ref.  
 75–84 389 (7) 33 (29.5) 5.73 (3.71-8.84)  5.58 (3.10-10.03)  
 ≥85 126 (2.3) 13 (11.6) 6.96 (3.73-12.99)  9.35 (4.31-20.30)  
 Born in the Netherlands** 1560 (28.1) 57 (51.8) 2.75 (1.88-4.02) 0.000 1.26 (0.75-2.12) 0.38 
 Urban domicile 1954 (35.1) 43 (38.4) 1.15 (0.78-1.69) 0.47 Not included - 
2 Current TB diagnosis 
      
 Pulmonary diagnosis    0.000  0.038 
 ETB 1876 (33.7) 14 (12.5) Ref.  Ref.  
 PTB 2951 (53.1) 61 (54.5) 2.77 (1.55-4.97)  4.04 (0.92-17.75)  
 ETB + PTB 735 (13.2) 37 (33) 6.75 (3.63-12.55)  4.97 (1.42-17.41)  
 Initial TB location    0.000  0.000 
 Lungs 3432 (61.7) 73 (65.2) 5.98 (2.75-13.01)  2.03 (0.45-9.04)  
 Central nervous system 57 (1) 13 (11.6) 64.09 (24.64-166.68)  120 (34.43-418.54)  
 Miliary 106 (1.9) 19 (17) 50.37 (20.72-122.45)  10.73 (2.50-46.02)  
 Others 1967 (35.4) 7 (6.3) Ref.  Ref.  
 TB diagnosis outside of the 
Netherlands 
49 (0.9) 1 (0.9) 1.01 (0.14-7.41) 0.98 Not included - 
3 History of TB disease & 
treatment 
      
 Previously diagnosed TB** 347 (6.7) 11 (14.5) 2.35 (1.23-4.49) 0.008 1.23 (0.61-2.48) 0.57 
 Previously treated LTBI** 182 (3.5) 2 (2.7) 0.76 (0.18-3.10) 0.69 Not included - 
4 Risk group of TB 
      
 TB contact 371 (6.7) 4 (3.6) 0.52 (0.19-1.4) 0.19 Not included - 
 Immigrants and asylum 
seekers 994 (17.9) 3 (2.7) 0.13 (0.04-0.40) 0.000 0.11 (0.01-0.84) 0.03 
 Illegal immigrants 200 (3.6) 1 (0.9) 0.24 (0.034-1.74) 0.19 Not included - 
 Homeless individuals 127 (2.3) 5 (4.5) 2.00 (0.80-4.99) 0.19 Not included - 
 Health care workers 45 (0.8) 1 (0.9) 1.10 (0.15-8.08) 0.60 Not included - 















area >3 month 
 Prisoners 143 (2.6) 0 (0) 0.17 (0.01-2.71) 0.21 Not included - 
 Alcohol addicts 109 (2) 2 (1.8) 0.91 (0.22-3.73) 0.89 Not included - 
 Drug addicts 146 (2.6) 6 (5.4) 2.10 (0.91-4.86) 0.12 3.56 (1.34-9.47) 0.01 
5 Comorbidities 
      
 Diabetes 256 (4.6) 12 (10.7) 2.49 (1.35-4.59) 0.003 1.10 (0.46-2.65) 0.84 
 Malignancy 128 (2.3) 7 (6.3) 2.83 (1.29 -6.20) 0.017 2.13 (0.89-5.11) 0.89 
 Renal insufficiency/dialysis 82 (1.5) 9 (8) 5.84 (2.86-11.94) 0.000 3.23 (1.17-8.96) 0.024 
 Organ transplantation 19 (0.3) 3 (2.7) 8.03 (2.34-27.53) 0.009 1.88 (0.18-19.54) 0.60 
 
Notes: * Number of analysed cases 5,674, Hosmer & Lemeshow test 0.59, area under curve 0.85 (0.82-0.88); n/a, not applicable due to a small number of 
event; Ref., reference; OR, odds ratio; aOR, adjusted odds ratio; **missing value: Country of birth 15 (0.3%), previously diagnosed TB 437 (7.7%), previously 




























Adult tuberculosis  
cases 2005-2015  
n = 10,303 
 
Others, n = 3,600 : 
1. Mycobacterium bovis (121) 
2. M. tb complex (582) 
3. Culture positive with unknown 
result (12) 
4. Negative result (1,546) 
5. Culture was not performed (769) 
6. Unknown result (570) 
 
M.tb confirmed  
n = 6,703 
 
Unknown outcome treatment, n = 294: 
1. DSTB cases with treatment 
continue elsewhere (192) 
2. DRTB cases with treatment 
continue elsewhere (44) 
3. No starting treatment (45) 
4. Not filled (13) 
Known outcome treatment 
n= 6,409 
 
Others, n = 735 : 
1. Mono or poly resistant H or R (392) 
2. Mono resistant E or Z (46) 
3. MDR (103) 
4. XDR (4) 
5. Culture positive with unknown 
result (190) 
 
DSTB confirmed  
n = 5,674 
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